TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

This spotlight features Filippo Milano, MD, PhD, a physician-scientist at Fred Hutch and ASTCT board member. As the inaugural Endowed Chair in Cord Blood Research, he shares his journey from Rome...

Researchers believe that engineering chimeric antigen receptor (CAR) T cells to recognize CD155 is a novel approach that could be appropriate for both hematologic and solid tumors.

Fludarabine is valued for its role in chimeric antigen receptor (CAR) T-cell therapy, but scientists believe moving away from fixed dosages could mediate better outcomes.

Research upholds the continued clinical value of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with Hodgkin lymphoma at a time when checkpoint inhibitors (CPIs) are...

Older adults preparing for allogeneic hematopoietic stem cell transplantation (allo-HSCT) may benefit from lower doses of fludarabine during reduced-intensity conditioning (RIC), researchers say.

In this episode of ASTCT Talks, Dr. Corey Cutler sits down with Dr. Ana Barata to discuss the critical role of physician-patient communication in GVHD and stem cell transplantation.